Veloxis Pharmaceuticals A/S - English Releaseshttp://investor.lcpharma.com/releases.cfm?sh_auth=0.0.0.ad1dcb691ef81696c0c02ea27e385165Veloxis Pharmaceuticals A/S - English Releasesen-usShareholder.com RSS FeedEuropean Medicines Agency (EMA) Accepts Veloxis' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant Patientshttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=766327Tue, 21 May 2013 18:06:07 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=766327European Medicines Agency (EMA) Accepts Veloxis' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant PatientsFinal STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremorshttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=765843Mon, 20 May 2013 06:30:00 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=765843Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced TremorsVeloxis Pharmaceuticals announces financial results for the first three months of 2013http://investor.lcpharma.com/releasedetail.cfm?ReleaseID=765016Wed, 15 May 2013 15:12:11 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=765016Veloxis Pharmaceuticals announces financial results for the first three months of 2013New Articles of Associationhttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=760775Wed, 01 May 2013 08:35:48 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=760775New Articles of AssociationVeloxis Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro™ for Treatment of Kidney Transplant Patientshttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=759906Mon, 29 Apr 2013 11:04:01 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=759906Veloxis Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro™ for Treatment of Kidney Transplant PatientsVeloxis Pharmaceuticals A/S - Passing of Ordinary General Meetinghttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=757086Wed, 17 Apr 2013 13:00:14 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=757086Veloxis Pharmaceuticals A/S - Passing of Ordinary General MeetingNotice to Convene Annual General Meetinghttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=750342Fri, 22 Mar 2013 08:59:09 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=750342Notice to Convene Annual General MeetingWarrant Programme - Registration of capital increase and new Articles of Association following warrant exercisehttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=745606Wed, 06 Mar 2013 12:41:06 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=745606Warrant Programme - Registration of capital increase and new Articles of Association following warrant exerciseWarrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants and announces trading in the company's shares by executiveshttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=745570Wed, 06 Mar 2013 09:42:07 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=745570Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants and announces trading in the company's shares by executivesVeloxis Pharmaceuticals Annual Report 2012http://investor.lcpharma.com/releasedetail.cfm?ReleaseID=745548Wed, 06 Mar 2013 07:51:01 GMThttp://investor.lcpharma.com/releasedetail.cfm?ReleaseID=745548Veloxis Pharmaceuticals Annual Report 2012